Videos
March 19, 2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical trials.
Videos
February 25, 2021
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Videos
February 24, 2021
Sagar Patel, MD, discusses utilization trends and survival outcomes among guideline-supported treatment options in older men with high-risk prostate cancer.
Videos
February 23, 2021
Tomasz Beer, MD, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic CRPC.
Videos
February 21, 2021
Felix Feng, MD, discusses results from exploratory analysis of the phase 3 SPARTAN trial, which investigated potential biological signatures of patients with nonmetastatic CRPC who achieved long-term responses to apalutamide and placebo.
Videos
February 20, 2021
Hala Borno, MD, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.
Videos
February 19, 2021
Vidit Sharma, MD, discusses a study exploring whether reductions in PSA screening are responsible for increased incidence of metastatic prostate cancer in the United States.
Videos
February 19, 2021
Eric Schwartz, MD, discusses results from an analysis examining out-of-pocket costs for patients with prostate cancer prescribed abiraterone or enzalutamide.